US EditionPrecision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show
- At ASCO 2025, Pfizer disclosed Phase 3 results demonstrating that combining Braftovi with cetuximab and chemotherapy substantially improved overall survival in patients with colorectal cancer harboring the BRAF V600E mutation.
- The trial followed over 600 patients who were randomized to receive either this three-drug combination or standard chemotherapy with or without bevacizumab as first-line treatment.
- The combination reduced mortality risk by 51%, improved median overall survival to 30.3 months versus 15.1 months for controls, and nearly halved disease progression risk with a median PFS of 12.8 months.
- Dr. Elena Elez called these the first promising survival outcomes for this aggressive colorectal cancer subtype and noted the results support a new standard of care with manageable side effects.
- These findings may change clinical practice by emphasizing biomarker testing for targeted therapy and could lead to full FDA approval, offering improved prognosis for about 10% of metastatic colorectal cancer patients.
15 Articles
15 Articles
New Study Shows Promising Results in Fight Against Colon Cancer
A new colon cancer study from Pfizer is revealing that a combination of medications can potentially cut the risk of death in half for people with a specific type of the disease. NBC News medical contributor Dr. Natalie Azar joins TODAY to break down the key takeaways from the trial, potential side effects, and more.
Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show
Pfizer drug Braftovi achieved statistically significant and clinically meaningful improvement in overall survival for colorectal cancer patients in a Phase 3 clinical trial. The results will be presented Friday during the annual meeting of the American Society of Clinical Oncology. The post Precision Pfizer Drug Leads to ‘Unprecedented’ Survival in Colorectal Cancer, Data at ASCO Show appeared first on MedCity News.
Immune-boosting drug ‘could change the world’ for cancer patients – warding off killer for years - New York Times Post
AN immune boosting drug can stave off throat cancer for years longer than current treatments, a trial found. Recovering head and neck cancer patients treated with pembrolizumab, also known as Keytruda, remained cancer-free for an average of five years. 2 Immunotherapy drug pembrolizumab could help cancer patients live longer, scientists sayCredit: Associated Press That was twice as long as the 2.5 years for patients given regular chemotherapy. …
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
